Lake Street analyst Ben Haynor initiated coverage of Femasys with a Buy rating and $1.50 price target. FemBloc is the first and only non-surgical alternative that can be performed in an OB/GYN office without incisions, anesthesia, or permanent implants and the device has CE Mark clearance and is currently in a registration trial for PMA approval from the FDA, notes the analyst. The latest data suggests about 1.2M surgical sterilizations occur in the U.S. each year, so this could be "a multi-billion-dollar market for Femasys in the U.S. alone," depending on average selling prices, the analyst tells investors.
